SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Thompson JA. Metastatic renal cell carcinoma: current standards of care. Clin J Oncol Nurs. 2009; 13( suppl): 8-12.
  • 2
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
  • 3
    Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996; 2: 1096-1103.
  • 4
    Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008; 14: 6674-6682.
  • 5
    Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009; 15: 2148-2157.
  • 6
    Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin. 2007; 57: 112-125.
  • 7
    Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009; 27: 1075-1081.
  • 8
    Kirkwood JM, Lorigan P, Hersey P, et al. A phase II trial of tremelimumab (CP-675206) in patients with advanced refractory or relapsed melanoma [poster and discussion]. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology (ASCO); May 30 to June 3, 2008; Chicago, Ill. Abstract 9023.
  • 9
    Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [oral presentation]. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology (ASCO); May 30 to June 3, 2008; Chicago, Ill. Abstract LBA9011.
  • 10
    Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675206. J Clin Oncol. 2005; 23: 8968-8977.
  • 11
    National Cancer Institute, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) [published August 9, 2006]. Bethesda, Md: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis; 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed June 1, 2010.
  • 12
    Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 4068-4075.
  • 13
    Gordon MS, Stein M, Shannon P, et al. Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) [poster presentation]. Presented at: 45th Annual Meeting of the American Society of Clinical Oncology (ASCO); May 29 to June 2, 2009; Orlando, Fla. Abstract 5115.
  • 14
    Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006; 24: 25-35.